Entrada Therapeutics Inc (TRDA)

Entrada Therapeutics' stock price has fluctuated in the past six months, with a closing price of $11.44 as of January 30, 2026. Key events impacting the stock include Q3 2025 financial results, a strategic plan and workforce reduction in April 2025, clinical program updates, and analyst coverage from Oppenheimer. In Q3 2025, the company reported a net loss of $(44.1) million and a decrease in collaboration revenue, but maintained a strong cash position. The company implemented a strategic plan to focus resources on its expanding DMD clinical candidates, which included a workforce reduction of approximately 20%. The company reported progress across its RNA-based programs for neuromuscular and ocular diseases.

As a clinical-stage biopharmaceutical company, Entrada Therapeutics, Inc. does not have commercial products on the market, and its revenue is primarily derived from collaboration agreements. Therefore, demand seasonality is not applicable, as its activities are driven by scientific milestones and regulatory processes.

Entrada Therapeutics, Inc. (TRDA) is a clinical-stage biopharmaceutical company focused on developing medicines targeting intracellular disease drivers using its proprietary Endosomal Escape Vehicle (EEV) platform. The company's pipeline is focused on neuromuscular diseases, including Duchenne muscular dystrophy (DMD) programs and a partnered program with Vertex Pharmaceuticals for myotonic dystrophy type 1 (DM1). As a clinical-stage company, its revenue is derived from collaboration agreements.

Entrada Therapeutics, Inc. is headquartered in Boston, Massachusetts. The company is conducting clinical studies for its Duchenne muscular dystrophy programs in the U.K., EU, and U.S.

Entrada Therapeutics is recognized for its mission to develop innovative therapies for unmet needs, particularly in Duchenne muscular dystrophy and myotonic dystrophy type 1. Its EEV technology is considered a key competitive advantage. The implementation of a strategic plan in April 2025, including a workforce reduction, could have impacted its corporate reputation. Analyst sentiment towards Entrada Therapeutics is largely positive.

Entrada Therapeutics, Inc. has a significant portion of its stock held by institutional investors, with estimates ranging from 42.52% to 86.39%. Major institutional owners include Baker Bros. Advisors Lp, MPM Asset Management Llc, and BlackRock, Inc. Felix Baker owns the most shares of Entrada Therapeutics, Inc. Insiders have sold more company stock than they have bought in the past three months.